Dec. 4, 2008-The European Medicines Agency has been formally notified by Oncoscience AG of its decision to withdraw its application for a centralised marketing authorisation for the medicine Theraloc (nimotuzumab), 5 mg/ml concentrate for solution for infusion.
The details can be read here.
No comments:
Post a Comment